How should factors such as del(17q) and IgHV mutations be leveraged to individualize treatment in CLL?
How do the latest data affect treatment selection for individual patients with newly diagnosed CLL who do not have specific genetic abnormalities?
How do the latest clinical data affect treatment selection for patients with relapsed/refractory CLL and the del(17p) genetic abnormality?
How I incorporate IgHV mutations status in my current clinical practice.
Do you know how recent CLL results presented at ASH 2016 could change your practice? Read my thoughts on ibrutinib and what to do after treatment failure.
In the past few years, striking progress has been made in the treatment of ibrutinib-refractory CLL. Read my thoughts on how these promising developments might be applied in your practice.
Historically, maintenance therapy was considered unnecessary for patients with CLL, but new data may change this practice for some of our patients.
Among the CLL studies presented at ASCO, these are the 5 that I feel have the most promise to be practice changing in the future.
In this text module with embedded slides, Jeffrey A. Jones, MD, MPH, reviews his approach to treating individual patients with CLL and provides the rationale for his choices.
In this downloadable slideset, Jeffrey A. Jones, MD, MPH, reviews his approach to treating individual patients with CLL and provides the rationale for his choices.
In this text module with corresponding downloadable slides, Andrew D. Zelenetz, MD, PhD, reviews the latest data behind his strategies for individualizing treatments for diverse patients with CLL.
In this downloadable slideset, Andrew D. Zelenetz, MD, PhD, reviews the latest data behind his strategies for individualizing treatments for diverse patients with CLL.
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Recent progress in the management of CLL makes CME and CE very important for medical professionals who care for these patients. Specifically, clinicians must consider multiple factors including the presence of specific cytogenetic markers, patient age, fitness, and comorbidities along with previous treatment history along with the available clinical evidence of safety and efficacy to identify which new targeted therapy or chemoimmunotherapy regimen is most appropriate for their patient.
Through CME and CE, clinicians stay up to date with all the latest research and developments in CLL and learn expert insights to help them apply the recent findings in the clinic to deliver high-quality care and optimize outcomes for patients with CLL.